The impact of aggressive debridement used as an adjunct therapy with terbinafine on perceptions of patients undergoing treatment for toenail onychomycosis

Journal of Dermatological Treatment

Volumn 18, Issue 1, 2007, Pages 46-52

  Potter, Lori P ^a   Mathias, Susan D ^a   Raut, Monika ^b,d   Kianifard, Farid ^b   Landsman, Adam ^c   Tavakkol, Amir ^b  

^a Ovation Research Group   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c HARVARD MEDICAL SCHOOL   (United States)

^d Ortho Biotech Products LP   (United States)

Author keywords

Debridement; Onychomycosis; PRO; Quality of life; Terbinafine

Indexed keywords

TERBINAFINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEBRIDEMENT; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; INFECTION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT SATISFACTION; PERCEPTION; PHYSICAL ACTIVITY; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; SEX; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE; STIGMA; SYMPTOM; SYMPTOMATOLOGY; TOENAIL ONYCHOMYCOSIS; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTIFUNGAL AGENTS; BOSTON; DEBRIDEMENT; FEMALE; FOOT DERMATOSES; HUMANS; MALE; MIDDLE AGED; NAILS; NAPHTHALENES; ONYCHOMYCOSIS; PROSPECTIVE STUDIES; QUESTIONNAIRES; SAN FRANCISCO; TREATMENT OUTCOME;

EID: 33947188032     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.1080/09546630600965004     Document Type: Article

References (13)

1. Elewski BE. The effect of toenail onychomycosis on patient quality of life. Int J Dermatol. 1997;36:754-6.
2. Lubeck DP, Patrick DL, McNulty P, Fifer SK, Birnbaum J. Quality of life of persons with onychomycosis. Qual Life Res. 1993;2:341-8.
3. Scher RK. Onychomycosis is more than a cosmetic problem. Br J Dermatol. 1994;130(suppl 43):15.
4. Gupta AK, Shear NH. A risk-benefit assessment of the newer oral antifungal agents used to treat onychomycosis. Drug Saf. 2000;22:33-52.
5. Sigurgeirsson B, Olafsson JH, Steinsson J, Paul C, Billstein S, Evans EG. Long-term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis: A 5-year blinded prospective follow-up study. Arch Dermatol. 2002;138:353-7.
6. Schein JR, Gause D, Stier DM, Lubeck DP, Bates MM, Fisk R. Onychomycosis. Baseline results of an observational study. J Am Podiatr Med Assoc. 1997;87:512-19.
7. Lubeck DP, Schein JR, Gause D, Prebil LA, Potter LP. Health-related quality of life in patients with toenail onychomycosis: Data from a 9-month observational study. J Clin Outcomes Manage. 1999;6(8):37-42.
8. Lubeck DP, Gause D, Schein JR, Prebil LE, Potter LP. A health-related quality of life measure for use in patients with onychomycosis: A validation study. Qual Life Res. 1999;8(1-2):121-9.
9. Drake LA, Patrick DL, Fleckman P, Andr J, Baran R, Haneke E, et al. The impact of onychomycosis on quality of life: Development of an international onychomycosis-specific questionnaire to measure patient quality of life. J Am Acad Dermatol. 1999;41(2 Pt 1):189-96.
10. Tavakkol A, Fellman S, Kianifard F. Safety and efficacy of oral terbinafine in the treatment of onychomycosis: Analysis of the elderly subgroup in the open-label, randomized Improving Results in Onychomycosis Concomitant Lamisil® and Debridement (IRON-CLAD®) trial. Am J Geriatr Pharmacother. 2006;4:1-13.
11. Jennings M, Pollack R, Harkless LB, Kianifard F, Tavakkol A. Treatment of toenail onychomycosis with oral terbinafine plus aggressive debridement: IRON-CLAD®, a large, randomized, open-label, multi-center trial. J Am Podiatr Med Assoc. 2006 (in press).
12. Potter L, Mathias S, Raut M, Kianifard F, Tavakkol A. The OnyCOE-t™ Questionnaire: Responsiveness and clinical meaningfulness of a patient-reported outcomes questionnaire for toenail onychomycosis. Health Qual Life Outcomes. 2006;4:50.
13. Kutner MH, Nachtsheim CI, Neter J, Li W. Applied linear statistical models. 5th ed. New York: McGraw-Hill/Irwin; 2005. Section 17.5; p. 746-53.